TECHNOLOGY DESCRIPTION
An innovative therapeutic solution developed with extracellular vesicles (EV)
for treatment of secondary damage effects on ischemic tissues.
Policlinico Hospital inventors select and isolate human mesenchymal stem cells, renowned
for their beneficial effects in pathological contexts of acute damage. After a reprogramming process (repCBMSC), they identified a specific set of miRNA able to modulate inflammation in both parental CBMSC-EV and repCBMSC-EV.This set of miRNA was successfully challenged in a model of brain ischemia, where necrosis was significantly reduced.
BENEFITS
- Protective/reparative effect correlated with significant tissue level reduction of apoptotic/inflammatory TNFα (4-fold) and INFγ (3-fold).
- Significant necrosis damage reduction.
LIMITATIONS
N.A.
APPLICATIONS
- Treatment or prevention of secondary damage effects on ischemic tissues.
- Treatment of acute or chronic neurodegenerative diseases with inflammatory
component.
MATERIALS
Readiness Level (TRL)
 Patent Grading Report |
Patent Grading ReportThe Grading Patents Report evaluates and grades US patents Sample Buy from Wisdomain |
STATUS
Current status
PCT Application
AVAILABILITY
Available for
Licensing
INVENTOR / TEAM
Mario Barilani, Lorenza Lazzari
